In search of improving balance sheets
With the election literally just hours away, there is so much uncertainty which is causing dramatic intraday / week swings in the market. This is led by the possibility that there will not be a decision on November 3rd, and further, any litigation that would be prolonged through Inauguration Day on January 20th, would ultimately hand the White House over to Nancy Pelosi.
In anticipation of this, investors are seeking safe haven in a balance of cash and defensive stocks.
StockNews.com just released an article titled “4 Top Stocks to buy in a Market Crash”
They cited Adobe, Inc. (NASDAQ: ADBE), Procter & Gamble (NYSE: PG), SolarEdge Technologies (NASDAQ: SEDG) and ITT, Inc. (NYSE: ITT).
The next few days may not turn into a significant downturn, but it’s good to be prepared, as the article suggests. Among other reasons these companies were selected, they have strong balance sheets.
Here is another company who has just reduced its debt by about 30% and has made a major difference in its own balance sheet.
On August 14, Pet Vivo Holdings, Inc. (OTCQB: PETV) filed its quarterly report for the period ending June 30, 2020. In it, it showed current liabilities of $2.14 million. Since then, the company settled over $600,000.00 in liabilities which is reflected in recent 8K “material event” filings, as well as in its next quarterly report.
Pet Vivo Holdings, Inc. (OTCQB: PETV) gives investors not only a vehicle to be defensive, but also a way to play the biotech space without playing roulette with which company is going to furnish approval for a covid-19 vaccine first.
Pet Vivo Holdings, Inc. (OTCQB: PETV) is up about 50% over its prior pivot in July trading at about $1.50 per share.
In a nutshell, PetVivo is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets.
KUSH, PETV’s lead product is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis (OA) in dogs and horses is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products. Sales in the $4.8 billion dog and horse therapeutics market is expected to begin shortly.
They just opened a state-of-the-art medical device manufacturing facility in Edina Minnesota, primarily dedicated to the manufacture of KUSH™ which will serve as the primary location for PetVivo’s medical device operations.
The facility includes over 600 square feet of state-of-the-art ISO 5, ISO 7 and ISO 8 cleanroom space, with plans for additional expansion and is dedicated exclusively to medical device manufacturing and product development.
It is staffed with a highly skilled team, led by a seasoned management team, and has the manufacturing capabilities to produce up to 500,000 syringes of Kush that could generate over $100 million in revenue annually.
Back in July, the stock was given a target price of between $1.74 and $2.32 per share by Marble Arch Research. You can download the full report here: – Among other results, the report states “At ~1x FY23 sales, the stock is substantially undervalued relative to its comps mostly trading in a comparable 3X-4X P/S multiple range.”
Since then, and as the stock looks like it could penetrate the previous projections, PetVivo Holdings, Inc. (OTCQB: PETV) just announced that a company out of Orlando, Florida called nScrypt that designs and manufactures high-precision industrial Micro-dispensing and Direct Digital Manufacturing equipment, has just successfully 3D bio-printed PetVivo’s (OTCQB: PETV) biomaterial for orthopedic implants using its Bio-Fabrication Tool (BAT).
PetVivo’s (OTCQB: PETV) biomaterial that can be printed using this tool is a proprietary blend of hydrated collagen, elastin, and heparin, the four main components that make up living tissue. To the best of the company’s knowledge, there is no other company that has the ability to provide these life-based components for the 3D printing marketplace.
Goldman Research just announced a new report with its current target price under review. You can see the report here:
The applications and cures for this technology are endless. Implants, replacements, up until and including the present, have been made with foreign ingredients like titanium and other metals. The future of this science now lies with the technology that allows for a more biologically familiar biomaterial. PetVivo’s biomaterial is made from the same components as the body’s natural tissue, allowing cells to be added to the structures being printed.
Ultimately, this breakthrough could lead to the creation of implants that actually mimic the bone itself.
PetVivo’s (OTCQB: PETV) press release goes on to read: “The PetVivo biomaterial, which consists of collagen, elastin, and heparin, can be used to create regenerative and/or biologically integrative medical devices, injected particles, coatings, and drug delivery vehicles. In addition, the PetVivo biomaterial can be combined with other biomaterials, enabling various kinds of implants to be created. PetVivo’s biomaterial technology is highly suited for the substitution or replacement of slower healing permanent implants used today, especially in orthopedic markets, such as spine and knee.”
Pet Vivo (OTCQB: PETV) also has a portfolio of 19 patents that protect the company’s pipeline of 16 products for the treatment of animals and people.
According to The American Pet Products Association, almost 85 million households have a pet and over the last 30 years pet ownership has gone from 56% to 68% of all households. If you are looking for an improved balance sheet in a defensive sector, have a look at Pet Vivo Holdings, Inc. (OTCQB: PETV).
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.